(Q53344976)

English

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

0 references

0 references

11

object named as

Califf RM

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

8

object named as

Zannad F

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

9

object named as

Swedberg K

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

author name string

O'Connor CM

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Gattis WA

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Uretsky BF

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Adams KF Jr

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

McNulty SE

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Grossman SH

6

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

McKenna WJ

7

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Gheorghiade M

10

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

language of work or name

0 references

publication date

1 July 1999

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

American Heart Journal

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

138

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

1 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

78-86

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Long-term benefit of dobutamine in patients with congestive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Short- and long-term dobutamine treatment in chronic ischemic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Intermittent dobutamine infusion in severe chronic heart failure in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Failure of dobutamine to increase exercise capacity despite hemodynamic improvement in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Symptoms, haemodynamics, and exercise capacity during long term treatment of chronic heart failure. Experience with pirbuterol

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Do positive inotropic agents adversely affect the survival of patients with chronic congestive heart failure? I. Introduction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Apoptosis in myocytes in end-stage heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970250-4

7 January 2021

Identifiers

10.1016/S0002-8703(99)70250-4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/10385768

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53344976&oldid=1371322615"